JAZZ - Jazz Pharmaceuticals plc
| Previous Close | 137.42 |
| Open | 138.22 |
| Bid | 0.01 x 800 |
| Ask | 141.95 x 800 |
| Day's Range | 135.85 - 138.76 |
| 52 Week Range | 113.52 - 184.00 |
| Volume | 447,151 |
| Avg. Volume | 621,114 |
| Market Cap | 7.749B |
| Beta (3Y Monthly) | 1.01 |
| PE Ratio (TTM) | 17.00 |
| EPS (TTM) | 8.05 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 172.67 |
- Zacks•yesterday
5 Best PEG Stocks Suitable for GARP Investors
While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.
- Markit•4 days ago
See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for JAZZ with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold JAZZ had net inflows of $2.38 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•5 days ago
JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
JAZZ vs. PCRX: Which Stock Is the Better Value Option?
- Zacks•8 days ago
Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- PR Newswire•9 days ago
Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals ...
- Thomson Reuters StreetEvents•12 days ago
Edited Transcript of JAZZ earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Jazz Pharmaceuticals PLC Earnings Call
- Zacks•15 days ago
3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
- Zacks•15 days ago
3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- PR Newswire•16 days ago
Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
Fourteen abstracts highlight Jazz's breadth in sleep medicine research and commitment to developing treatment options for people living with debilitating sleep disorders DUBLIN , May 9, 2019 /PRNewswire/ ...
- Zacks•17 days ago
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.
- Motley Fool•18 days ago
Jazz Pharmaceuticals Hits All the Right Notes in Q1
The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.
Motley Fool•18 days agoJazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript
JAZZ earnings call for the period ending March 31, 2019.
- Zacks•18 days ago
Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 16.14% and 7.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 days ago
Jazz: 1Q Earnings Snapshot
The Dublin-based company said it had net income of $1.47 per share. Earnings, adjusted for one-time gains and costs, were $3.67 per share. The results topped Wall Street expectations. The average estimate ...
- PR Newswire•18 days ago
Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
Total Revenues Increased 14% to $508 Million GAAP Diluted EPS of $1.47 ; Adjusted Diluted EPS of $3.67 Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy ...
GuruFocus.com•18 days ago5 Stocks With Low Price-Earnings Ratios
According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios. Shares of Patrick Industries Inc. (PATK) are trading around $48.59 with a price-sales ratio of 0.52 and a price-earnings ratio of 9.86. Warning! GuruFocus has detected 2 Warning Sign with PATK.
- PR Newswire•19 days ago
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
DUBLIN, May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Dan Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
- Simply Wall St.•19 days ago
What Should Investors Know About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Earnings Outlook?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) latest earnings announcement in December 2018 signalled...
- Zacks•23 days ago
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
- Zacks•25 days ago
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•26 days ago
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- PR Newswire•last month
Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019
DUBLIN , April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019 , after the close of ...
